Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

GM Bartelds, CLM Krieckaert, MT Nurmohamed… - Jama, 2011 - jamanetwork.com
Context Short-term data on the immunogenicity of monoclonal antibodies showed associations
between the development of antidrug antibodies and diminished serum drug levels, and …

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

…, E De Groot, MT Nurmohamed… - Arthritis & …, 2006 - Wiley Online Library
Objective Treatment of patients with infliximab, a chimeric monoclonal IgG1 antibody against
tumor necrosis factor, may result in the formation of infliximab‐specific IgG antibodies. This …

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

…, CA Wijbrandts, MT Nurmohamed… - Annals of the …, 2007 - ard.bmj.com
Background: A substantial proportion of patients with rheumatoid arthritis (RA) do not respond,
or lose initial response, to adalimumab treatment. One explanation for non-response is …

Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study

…, BAC Dijkmans, MT Nurmohamed - Arthritis Care & …, 2009 - Wiley Online Library
Objective Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular
disease (CVD), but longitudinal observations are limited and the precise magnitude is …

Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis

…, BA Dijkmans, MT Nurmohamed - Seminars in arthritis and …, 2004 - Elsevier
OBJECTIVE: To evaluate the cardiovascular risk profile of spondylarthropathy patients,
particularly ankylosing spondylitis and psoriatic arthritis. METHODS: A Pubmed literature search …

EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and …

…, GJ Macfarlane, MM Ward, MT Nurmohamed… - Annals of the …, 2022 - ard.bmj.com
Objective To develop recommendations for cardiovascular risk (CVR) management in gout,
vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD), …

Cardiovascular comorbidity in rheumatic diseases

MT Nurmohamed, M Heslinga, GD Kitas - Nature Reviews …, 2015 - nature.com
Patients with rheumatoid arthritis (RA) and other inflammatory joint diseases (IJDs) have an
increased risk of premature death compared with the general population, mainly because of …

[HTML][HTML] Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study

VP van Halm, MT Nurmohamed, JWR Twisk… - Arthritis research & …, 2006 - Springer
Rheumatoid arthritis (RA) is characterized by inflammation and an increased risk for
cardiovascular disease (CVD). This study investigates possible associations between CVD and the …

Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies

…, M Boers, MT Nurmohamed, T Rispens… - The Lancet …, 2021 - thelancet.com
Background Data are scarce on immunogenicity of COVID-19 vaccines in patients with
autoimmune diseases, who are often treated with immunosuppressive drugs. We aimed to …

Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review

…, N Sattar, I MciInnes, MT Nurmohamed - Annals of the …, 2013 - ard.bmj.com
Objective Data regarding cardiovascular comorbidity and cardiovascular risk factors in
patients with psoriatic arthritis (PsA) are limited. To evaluate the cardiovascular risk profile, a …